ZYTIGA
Total Payments
$11.8M
Transactions
27,202
Doctors
7,472
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $919,570 | 22 | 0 |
| 2023 | $354,134 | 18 | 4 |
| 2022 | $112,548 | 70 | 39 |
| 2021 | $145,053 | 56 | 21 |
| 2020 | $57,816 | 75 | 46 |
| 2019 | $1.3M | 702 | 327 |
| 2018 | $3.8M | 9,254 | 4,033 |
| 2017 | $5.1M | 17,005 | 5,610 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.3M | 560 | 87.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $559,000 | 10 | 4.7% |
| Food and Beverage | $420,499 | 24,770 | 3.6% |
| Consulting Fee | $290,884 | 95 | 2.5% |
| Education | $117,082 | 1,695 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $57,050 | 24 | 0.5% |
| Travel and Lodging | $23,161 | 48 | 0.2% |
Payments by Type
Research
$10.3M
560 transactions
General
$1.5M
26,642 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Research agreement between Janssen Research & Development, LLC and Johns Hopkins University Prostatic Carcinoma study | Janssen Research & Development, LLC | $1.6M | 0 |
| Can High grade PIN be Distinguished from Intra-acinar Spread of Prostatic Carcinoma | Janssen Research & Development, LLC | $832,797 | 0 |
| A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | Janssen Research & Development, LLC | $762,563 | 0 |
| Johns Hopkins University Prostatic Carcinoma | Janssen Research & Development, LLC | $732,795 | 0 |
| A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy | Janssen Research & Development, LLC | $574,921 | 0 |
| A Multicenter, Open-Label, Single-arm Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease | Janssen Research & Development, LLC | $555,684 | 0 |
| A Dynamic Allocation Modular Sequential Trial Of Approved And Promising Therapies In Men With Metastatic Castrate Resistant Prostate Cancer | Janssen Research & Development, LLC | $552,772 | 0 |
| Phase II clinical trial of abiraterone acetate without exogenous glucocorticoids in men with castration-resistant prostate cancer with correlative assessment of hormone intermediates | Janssen Research & Development, LLC | $455,441 | 0 |
| A Phase II open-label, parallel group study of abiraterone acetate in African American and Caucasian men with metastatic castrate-resistant prostate cancer | Janssen Research & Development, LLC | $386,506 | 0 |
| A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical | Janssen Research & Development, LLC | $370,915 | 0 |
| A Multi Center study of Androgen Suppression with abiraterone acetate Leuprolide PARP Inhibition and Stereotactic body radiotherapy ASCLE PIuS A phase I2 trial in high risk or node positive prostate cancer | Janssen Research & Development, LLC | $348,273 | 0 |
| Study of Androgen Receptor Signaling in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate | Janssen Research & Development, LLC | $271,726 | 0 |
| A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer | Janssen Research & Development, LLC | $229,337 | 0 |
| Characterize immune checkpoint expression on circulating tumor cells from distinct populations of mCRPC and correlate CTC and tumor mRNA and protein immune checkpoint expression. | Janssen Research & Development, LLC | $226,010 | 0 |
| A Phase II open label Multi Center study of Apalutamide Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate resistant prostate cancer | Janssen Research & Development, LLC | $205,410 | 0 |
| Niraparib/abiraterone efficacy/biomarker studies in LuCaP models at U Washington | Janssen Research & Development, LLC | $200,822 | 0 |
| A Pre-Operative Study to Assess the Effects of Abiraterone acetate plus LHRH Agonist and Abiraterone acetate plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-risk for Recurrence | Janssen Research & Development, LLC | $164,927 | 0 |
| ARN-509 + Abiraterone + Leuprolide with Stereotactic, UltraHypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer | Janssen Research & Development, LLC | $153,804 | 0 |
| Impact of Oral mCRPC Therapies | Janssen Scientific Affairs, LLC | $152,040 | 0 |
| A Phase II Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC) | Janssen Research & Development, LLC | $130,230 | 0 |
Top Doctors Receiving Payments for ZYTIGA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Memphis, TN | $10.9M | 591 |
| , M.D | Diagnostic Radiology | Boston, MA | $69,675 | 5 |
| , MD MPH | Diagnostic Radiology | Boston, MA | $26,690 | 6 |
| , MD | Urology | Livonia, MI | $15,860 | 21 |
| , M.D | Urology | Durham, NC | $15,254 | 12 |
| , MD | Urology | Troy, MI | $14,019 | 25 |
| , M.D | Medical Oncology | Baltimore, MD | $10,508 | 14 |
| , M.D | Urology | Philadelphia, PA | $8,745 | 7 |
| , MD | Internal Medicine | Philadelphia, PA | $8,613 | 4 |
| , DR | Urology | Myrtle Beach, SC | $8,137 | 24 |
| , MD | Urology | Springfield, OR | $7,490 | 26 |
| , M.D | Diagnostic Radiology | Boston, MA | $7,360 | 2 |
| , MD | Urology | Aurora, CO | $6,944 | 8 |
| , MD | Urology | Bryn Mawr, PA | $6,394 | 14 |
| , M.D | Hematology & Oncology | Edmonds, WA | $6,305 | 3 |
| , M.D | Urology | Fresno, CA | $5,119 | 10 |
| , MD | Hematology & Oncology | Boston, MA | $5,107 | 5 |
| , M.D | Hematology & Oncology | Massillon, OH | $5,040 | 6 |
| , M.D | Medical Oncology | Ocala, FL | $4,891 | 4 |
| , M.D | Hematology & Oncology | Mesquite, TX | $4,832 | 4 |
| , M.D | Urology | Marietta, GA | $4,775 | 12 |
| , MD | Hematology & Oncology | Cincinnati, OH | $4,407 | 8 |
| , M.D | Hematology & Oncology | Rock Hill, SC | $4,369 | 13 |
| , MD | Hematology & Oncology | Denver, CO | $4,204 | 3 |
| , M.D | Hematology & Oncology | Houston, TX | $3,986 | 3 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $10.2M
- Janssen Biotech, Inc. $503,791
- Johnson & Johnson Health Care Systems Inc. $500,615
- Janssen Scientific Affairs, LLC $330,698
- Janssen Products, LP $151,771
- Janssen Pharmaceuticals, Inc $73,478
- Janssen Global Services, LLC $7,594
Product Information
- Type Drug
- Total Payments $11.8M
- Total Doctors 7,472
- Transactions 27,202
About ZYTIGA
ZYTIGA is a drug associated with $11.8M in payments to 7,472 healthcare providers, recorded across 27,202 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $919,570 was paid across 22 transactions to 0 doctors.
The most common payment nature for ZYTIGA is "Unspecified" ($10.3M, 87.6% of total).
ZYTIGA is associated with 20 research studies, including "Research agreement between Janssen Research & Development, LLC and Johns Hopkins University Prostatic Carcinoma study" ($1.6M).